Long-term follow-up of patients with systemic AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation after induction and mobilisation chemotherapy

被引：0
|
作者：
Schonland, S. O. [1 ]
Bochtler, T. [1 ]
Hansberg, M. [1 ]
Mangatter, A. [1 ]
Perz, J. B. [1 ]
Ho, A. D. [1 ]
Goldschmidt, H. [1 ]
Hegenbart, U. [1 ]
机构：
[1] Univ Heidelberg, Heidelberg, Germany
来源：
BONE MARROW TRANSPLANTATION | 2008年 / 41卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S65 / S66
页数：2
相关论文
共 50 条
  • [21] Results of two consecutive phase II trials of patients with systemic AL amyloidosis treated with high-dose melphalan after induction and mobilisation chemotherapy
    Schonland, S. O.
    Bochtler, T.
    Perz, J.
    Hansberg, M.
    Mangatter, A.
    Ho, A. D.
    Goldschmidt, H.
    Hegenbart, U.
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2010, 17 : 80 - 81
  • [22] Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation
    Seldin, DC
    Anderson, JJ
    Sanchorawala, V
    Malek, K
    Wright, DG
    Quillen, K
    Finn, KT
    Berk, JL
    Dember, LM
    Falk, RH
    Skinner, M
    BLOOD, 2004, 104 (06) : 1888 - 1893
  • [23] High-dose melphalan chemotherapy with autologous stem cell transplantation in patients with AL amyloidosis: No increased mortality using induction and mobilization chemotherapy.
    Schonland, SO
    Hegenbart, U
    Dengler, JB
    Benner, A
    Hundemer, M
    Bochtler, T
    Ho, AD
    Goldschmidt, H
    BLOOD, 2005, 106 (11) : 464B - 465B
  • [24] Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study
    Bochtler, Tilmann
    Hegenbart, Ute
    Kunz, Christina
    Benner, Axel
    Kimmich, Christoph
    Seckinger, Anja
    Hose, Dirk
    Goldschmidt, Hartmut
    Granzow, Martin
    Dreger, Peter
    Ho, Anthony D.
    Jauch, Anna
    Schoenland, Stefan O.
    BLOOD, 2016, 128 (04) : 594 - 602
  • [25] Long-term follow-up of health status in patients with severe rheumatoid arthritis after high-dose chemotherapy followed by autologous stem cell transplantation
    Teng, YKO
    Verburg, RJ
    Sont, JK
    Van den Hout, WB
    Breedveld, FC
    van Laar, JM
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 185 - +
  • [26] Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis
    Gupta, Vishal K.
    Brauneis, Dina
    Shelton, Anthony C.
    Quillen, Karen
    Sarosiek, Shayna
    Sloan, J. Mark
    Sanchorawala, Vaishali
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (05) : E169 - E173
  • [27] Autologous Stem Cell Transplantation (ASCT) Versus Oral Melphalan and High-Dose Dexamethasone In Patients with AL (Primary) Amyloidosis: Long Term Follow-up of the French Multicentric Randomized Trial
    Jaccard, Arnaud
    Leblond, Veronique
    Royer, Bruno
    Leleu, Xavier
    Delarue, Richard
    Kolb, Brigitte
    Deconinck, Eric
    Stamatoullas, Aspasia
    Coppo, Paul
    Arnulf, Bertrand
    Hermine, Olivier
    Moreau, Philippe
    Fermand, Jean Paul
    BLOOD, 2010, 116 (21) : 576 - 577
  • [28] Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation in Sweden, long-term results from all patients treated in 1994-2009
    Rosengren, S.
    Mellqvist, U-H
    Nahi, H.
    Forsberg, K.
    Lenhoff, S.
    Stromberg, O.
    Ahlberg, L.
    Linder, O.
    Carlson, K.
    BONE MARROW TRANSPLANTATION, 2016, 51 (12) : 1569 - 1572
  • [29] Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem cell transplantation: 20-year experience
    Sanchorawala, Vaishali
    Sun, Fangui
    Quillen, Karen
    Sloan, J. Mark
    Berk, John L.
    Seldin, David C.
    BLOOD, 2015, 126 (20) : 2345 - 2347
  • [30] Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation
    P Corradini
    C Tarella
    F Zallio
    A Dodero
    M Zanni
    P Valagussa
    A M Gianni
    A Rambaldi
    T Barbui
    S Cortelazzo
    Leukemia, 2006, 20 : 1533 - 1538
12345